ise specified.
In healthy subjects who received 800 mg three times daily alone, boceprevir drug exposure was characterized by AUC(т) of 5408 ng.hr/mL (n=71), Cmax of 1723 ng/mL (n=71), and Cmin of 88 ng/mL (n=71). Pharmacokinetic results were similar between healthy subjects and HCV-infected subjects.
Absorption
Boceprevir was absorbed following oral administration with a median Tmax of 2 hours. Steady state AUC, Cmax, and Cmin increased in a less-than-dose-proportional manner and individual exposures overlapped substantially at 800 mg and 1200 mg, suggesting diminished absorption at higher doses. Accumulation is minimal (0.8- to 1.5-fold) and pharmacokinetic steady state is achieved after approximately 1 day of three times daily dosing.
The absolute bioavailability of boceprevir has not been studied.
Effects of Food on Oral Absorption
VICTRELIS should be administered with food. Food enhanced the exposure of boceprevir by up to 65% at the 800 mg three times daily dose, relative to the fasting state. The bioavailability of boceprevir was similar regardless of meal type (e.g., high-fat vs. low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. Therefore, VICTRELIS may be taken without regard to either meal type or timing of the meal.
Distribution
Boceprevir has a mean apparent volume of distribution (Vd/F) of approximately 772 L at steady state in healthy subjects. Human plasma protein binding is approximately 75% following a single dose of boceprevir 800 mg. Boceprevir is administered as an approximately equal mixture of two diastereomers, SCH534128 and SCH534129, which rapidly interconvert in plasma. The predominant diastereomer, SCH534128, is pharmacologically active and the other diastereomer is inactive.
Metabolism
Studies in vitro indicate that boceprevir primarily undergoes metabolism through the aldo-ketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV. After a single 800-mg oral dose of 14C-boceprevir, the most abundant circulating metabolites were a diasteriomeric mixture of ketone-reduced metabolites with a mean exposure approximately 4-fold greater than that of boceprevir. Boceprevir also undergoes, to a lesser extent, oxidative metabolism mediated by CYP3A4/5.
Drug Interactions
Drug interaction studies were performed with boceprevir and drugs likely to be coadministered or drugs commonly used as probes for pharmacokinetic interactions. The effects of coadministration of boceprevir on AUC, Cmax and Cmin are summarized in Table 6 (effects of coadministered drugs on boceprevir) and Table 7 (effects of boceprevir on coadministered drugs).
Table 6 Summary of the Effect of Co-administered Drugs on Boceprevir in Healthy Subjects or HCV Positive Genotype-1 Subjects Co-administered Drug Co-administered Drug Dose/Schedule Boceprevir Dose/Schedule Ratio Estimate of Boceprevir Pharmacokinetic Parameters (in Combination vs. Alone)
(90% CI of the Ratio Estimate) *
Change in mean Cmax Change in mean AUC Change in mean Cmin
N/A = not available
Ketoconazole 400 mg two times daily × 6 days 400 mg single oral dose 1.41
(1.00–1.97) 2.31
(2.00–2.67) N/A
Ibuprofen 600 mg three times daily × 6 days 400 mg single oral dose 0.94
(0.67–1.32) 1.04
(0.90–1.20) N/A
Diflunisal 250 mg two times dai |
